Christian T. Ruff

Jan 23, 2025 | hcplive.com | Christian T. Ruff |Abigail Brooks |Connor Iapoce

Results from the Phase 2b AZALEA-TIMI 71 trial showed abelacimab, a novel factor XI inhibitor, achieved key reductions in bleeding events versus a standard-of-care direct-oral anticoagulant (DOAC) in patients with atrial fibrillation (AF).1 Announced by Anthos Therapeutics, Inc., and published in The New England Journal of Medicine, abelacimab 150 mg lowered major or clinically relevant non-major bleeding by 62%, compared with rivaroxaban 20 mg, in a population with AF at moderate-to-high...

Jan 23, 2025 | consultantlive.com | Christian T. Ruff |Abigail Brooks |Connor Iapoce

Results from the Phase 2b AZALEA-TIMI 71 trial showed abelacimab, a novel factor XI inhibitor, achieved key reductions in bleeding events versus a standard-of-care direct-oral anticoagulant (DOAC) in patients with atrial fibrillation (AF).1 Announced by Anthos Therapeutics, Inc., and published in The New England Journal of Medicine, abelacimab 150 mg lowered major or clinically relevant non-major bleeding by 62%, compared with rivaroxaban 20 mg, in a population with AF at moderate-to-high...

Nov 17, 2024 | hcplive.com | Connor Iapoce |Christian T. Ruff

A new analysis of the AZALEA-TIMI 71 study showed abelacimab, a novel factor XI inhibitor, achieved consistent reductions in bleeding risk for patients on or off antiplatelet (APT) therapy, compared with rivaroxaban. Presented at the American Heart Association (AHA) Scientific Sessions 2024, these findings on the effect of abelacimab may offer a potentially safer option for patients with atrial fibrillation (AF) who experience an elevated bleeding risk with traditional anticoagulants.

Jan 25, 2024 | emjreviews.com | Christian T. Ruff

Since its earliest days, the effective use of anticoagulation for prevention of stroke and other thromboembolic events has been limited by the risk and fear of bleeding, which was long believed to be inevitable. However, new understanding of the coagulation cascade suggests that, by targeting factor XI, it may be possible to protect patients from pathological thrombosis without significantly affecting physiological haemostasis, and thus greatly reduce the risk of bleeding.

Nov 12, 2023 | healio.com | Erik Swain |Richard Smith |Christian T. Ruff |Christine M Albert

You've successfully added Cardiology: Arrhythmia Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: In patients with AF requiring anticoagulation, the factor XI inhibitor abelacimab greatly reduced bleeding risk compared with rivaroxaban.